Ashwagandha for Fatty Liver: Evidence, NAFLD & Safety
Most people discover ashwagandha for its stress or sleep benefits. But a different question keeps surfacing in our inbox: what does it actually do to the liver? Embedded within that question are two very different concerns — and both deserve honest, evidence-based answers. We call this framework “the Hepatic Burden Equation”: the liver is a clearance organ under constant load from metabolic waste, environmental toxins, medications, and chronic stress. Ashwagandha interacts with this equation in multiple directions — some potentially supportive, some potentially cautionary — and the balance matters enormously depending on your individual circumstances.
The first concern is whether ashwagandha might support liver function through its antioxidant activity and cortisol-modulating effects. The second is whether it might harm the liver — a legitimate concern given published case reports of liver injury attributed to ashwagandha-containing products, including an eight-patient case series from India where three patients with pre-existing liver disease died (PMID: 37756041).
Let us be direct from the outset: the evidence base for ashwagandha’s direct effects on the liver is substantially thinner than its evidence base for stress, sleep, and cognitive function. Most studies on the hepatoprotective mechanism were animal or in vitro. No human RCT has tested ashwagandha as a treatment for any liver condition. We will tell you exactly what that means in practice.
The Hepatic Burden Equation: What It Means
Your liver performs over 500 distinct functions. Among the most relevant to ashwagandha are three: metabolic detoxification (clearing hormones, drugs, and metabolic waste through cytochrome P450 enzyme systems), antioxidant defence (producing glutathione and superoxide dismutase to neutralise oxidative damage), and inflammatory regulation (the liver is a major site of both acute-phase protein production and systemic inflammatory signalling).
Chronic psychological stress places measurable load on all three. Elevated cortisol increases hepatic gluconeogenesis, driving metabolic strain. Sustained stress depletes antioxidant reserves. And the HPA axis — the hormonal cascade connecting your brain, adrenal glands, and liver — runs directly through hepatic tissue.
This is the Hepatic Burden Equation: the liver does not operate in isolation from your stress response. Whatever reduces chronic cortisol load may, secondarily, reduce hepatic burden. Ashwagandha’s stress-modulating mechanism is its most established human evidence — and it is through this lens that indirect hepatic benefits are theorised.
Safety Studies: What the Liver Enzyme Data Shows
The most relevant human data for liver safety comes from randomised controlled trials that included liver enzyme monitoring as part of their safety protocols. These studies also inform the broader picture of ashwagandha’s metabolic safety profile.
A 2021 randomised, double-blind, placebo-controlled safety study (PMID: 33338583, n=80, 8 weeks) specifically assessed ashwagandha root extract safety in healthy volunteers. The study evaluated hepatotoxicity markers including AST, ALT, ALP, and total bilirubin at baseline and week 8. At doses of 300mg twice daily of standardised root extract, no clinically significant changes in liver function markers were observed. No adverse events were reported by any participant.
A 2025 prospective RCT examining ashwagandha root extract for stress and weight management (PMID: 41635453, n=60, 12 weeks, double-blind) included comprehensive safety blood panels — including hepatic markers — and found no significant effect on liver enzyme levels compared to placebo. The research topics flagged by this study specifically included “liver_hepato” as a safety domain, confirming the researchers actively monitored for hepatic signals.
A 2026 three-arm RCT (PMID: 41815853, n=141, 8 weeks) evaluating a proprietary ashwagandha root extract at 300mg twice daily assessed safety through clinical adverse events and laboratory parameters, reporting that the extract “is considered an effective and safe intervention.”
A systematic review and meta-analysis reviewing ashwagandha in diabetes-adjacent metabolic conditions (PMID: 31975514, 24 studies) similarly found no signal of hepatotoxicity in human subjects receiving standardised root extract preparations.
The key qualifier: these findings apply specifically to standardised root extract preparations in healthy adults at doses used in studies (300–600mg/day) for defined study periods (8–16 weeks). They do not necessarily extend to non-root preparations, adulterated products, very high doses, or individuals with pre-existing liver disease.
The Case Report Problem: Understanding Reported Liver Injury
Here is the section most supplement brands omit. We will not.
The most rigorous evidence of ashwagandha-associated liver injury comes from a 2023 multi-centre case series from India (PMID: 37756041). Out of 23 patients identified with liver injury from ashwagandha between 2019 and 2022, the researchers excluded those taking multi-ingredient formulations and reported on 8 patients using single-ingredient ashwagandha products. Chemical analysis of the implicated products revealed only natural phytochemicals — no adulteration or contamination.
“Ashwagandha-HILI presents with cholestatic hepatitis and can lead to the syndrome of acute-on-chronic liver failure with high mortality in those with pre-existing liver disease.” — Philips et al., 2023 (PMID: 37756041)
The findings were significant: cholestatic hepatitis was the commonest presentation, five of eight patients had underlying chronic liver disease, three developed acute-on-chronic liver failure, and all three died on follow-up. In patients without pre-existing liver disease, the injury was prolonged but self-limiting.
Additional case reports have been published from Poland (PMID: 36900932 — cholestatic liver damage requiring plasmapheresis), the United Kingdom (PMID: 34882134 — acute cholestatic hepatitis with confluent necrosis), and Bosnia-Herzegovina (PMID: 37631044 — two cases scoring “probable” on the RUCAM causality scale).
Several important caveats apply to interpreting these reports:
- Pre-existing liver disease multiplied the risk dramatically: In the India series, all three deaths occurred in patients with underlying chronic liver disease. Healthy individuals recovered.
- Dose and duration varied widely: Several cases involved high doses (450mg three times daily in the Bosnia cases) or prolonged use (six months to one year)
- Genetic susceptibility may play a role: Variants in CYP450 enzymes that metabolise withanolides may create individual susceptibility that is not predictable in advance
- Resolution upon cessation: In patients without pre-existing liver disease, liver enzyme elevations resolved after discontinuing the supplement
The honest position is this: the frequency of these events appears low relative to the estimated millions of people taking ashwagandha worldwide, but the events are real, are published in peer-reviewed literature, and cannot be dismissed. A 2025 safety review (PMID: 41454545) concluded that ashwagandha “poses significant risks to specific populations” including individuals with liver dysfunction, and recommended restricting its use in those groups.
The Antioxidant Argument: Preclinical Hepatoprotective Data
Beyond safety, is there any positive evidence that ashwagandha might support liver function? Here the data is almost entirely preclinical.
A 2019 study from the National Cancer Institute (PMID: 31420528) tested withaferin A — a steroidal lactone found in ashwagandha — in two mouse models of non-alcoholic steatohepatitis (NASH). In both models, withaferin A prevented and therapeutically improved liver injury, reducing serum aminotransferases, hepatic steatosis, inflammation, and fibrosis. The study demonstrated a leptin-independent mechanism, suggesting the hepatoprotective effect was not simply secondary to weight loss.
A 2021 study (PMID: 33574236) found withaferin A alleviated fulminant hepatitis in mice by targeting macrophages and partially through NLRP3 inflammasome antagonism. Both preventive and therapeutic dosing showed benefit.
Earlier studies reinforce this pattern: glycowithanolides attenuated iron-overload-induced hepatotoxicity in rats comparably to silymarin (PMID: 11054855), and a withanolide-rich fraction protected against acetaminophen-induced liver injury by downregulating TNF-α and IL-1β (PMID: 27043749). A 2022 pharmacokinetic review (PMID: 34903587) highlighted significant gaps in translating these findings to human use.
These are interesting findings. However, a critical distinction applies: withaferin A studied in isolation at controlled doses in mice did not demonstrate the same risk profile as whole-plant ashwagandha supplements consumed by humans with varying genetics, liver health, and co-medications. Furthermore, a 2024 in vitro study on withanolides and hepatic lipid accumulation (PMID: 39596320) showed no benefit at higher concentrations, finding that only low, non-toxic doses of withaferin A possessed anti-steatosis properties — underscoring the narrow therapeutic window. The gap between promising laboratory findings and demonstrated human benefit is precisely where most hepatoprotective botanical claims fail scrutiny.
No human RCT has tested ashwagandha as a treatment for NAFLD, hepatitis, or any other hepatic condition. This is the current state of the evidence. We say this not to discourage interest in ashwagandha, but because this is the factual position and you deserve to know it.
The Cortisol Connection: Indirect Hepatic Effects
The most evidence-grounded pathway by which ashwagandha might support liver health is indirect: through cortisol reduction.
Chronic cortisol elevation drives hepatic gluconeogenesis, promotes visceral adiposity (associated with NAFLD risk), and suppresses hepatic insulin signalling.
A 2025 meta-analysis (PMID: 40746175) confirmed ashwagandha produces significant cortisol reduction across multiple RCTs, though it found no significant difference between ashwagandha and placebo for perceived stress — an important nuance showing cortisol reduction does not always translate to subjective benefit. For a deeper review of the stress evidence, see our anxiety and stress article and our mood support article.
If sustained cortisol reduction reduces hepatic gluconeogenic burden and visceral adiposity, this would theoretically translate to reduced liver load. This remains theoretical in humans but is mechanistically coherent. You may want to consider ashwagandha for stress reduction alongside lifestyle measures rather than as a standalone liver-support supplement.
Cytochrome P450 Interactions: The Medication Risk Layer
The Hepatic Burden Equation has a pharmacokinetic dimension that warrants explicit discussion.
Cytochrome P450 enzymes — particularly CYP3A4, CYP2D6, and CYP2C9 — are responsible for metabolising both withanolides and a significant proportion of commonly prescribed medications. In vitro studies and limited pharmacokinetic data suggest that ashwagandha may inhibit or induce some CYP450 activity, potentially altering the effective plasma concentrations of co-administered drugs.
This is particularly relevant for medications with narrow therapeutic indices: warfarin, cyclosporine, certain anticonvulsants, and some statins. Ashwagandha is not suitable for people on immunosuppressants without explicit medical clearance.
If you are taking any hepatically-metabolised medication, consult your healthcare professional before starting ashwagandha. This reflects a real mechanism with clinical implications that research has not yet fully characterised.
From Our Formulations
The DILI case reports in the published literature are disproportionately associated with products of variable quality, unclear provenance, and non-standardised preparations. This makes formulation specifics unusually important when evaluating ashwagandha for any use — and particularly so for liver safety.
Our ashwagandha is a root-only dual extract (hot water + ethanol, 10:1 extraction ratio), sourced from India using traditional di Tao sourcing principles. This matters because:
- Root-only, leaf-free: The root contains the primary adaptogenic withanolides. Leaf preparations have a different phytochemical profile — with higher concentrations of withaferin A — and are more commonly associated with adverse event reports. Our extraction uses root exclusively.
- ≥2.5% withanolides by HPLC: This is verified on every batch through certificate of analysis. The 2.5% threshold maintains full-spectrum, root-only, certified organic integrity. Higher percentages typically indicate leaf material or non-organic extraction methods — a point Teelixir’s formulator (Peter) emphasises when comparing to commodity ashwagandha products.
- Dual extraction (hot water + ethanol): This process extracts both water-soluble and alcohol-soluble withanolides, delivering a broader spectrum of bioactive compounds than single-solvent extraction.
- Heavy metal tested every batch: Lead, arsenic, cadmium, and mercury testing — because what enters your body directly affects the metabolic load your liver must process
- Microbiological clearance: E. coli negative, Salmonella negative on every batch
- ACO (Australian Certified Organic): Third-party organic certification, not self-declared
A low-quality, multi-ingredient product carries a categorically different risk profile from a pure, standardised, tested root extract. When the India case series (PMID: 37756041) found “only natural phytochemicals without adulteration,” the implication is that even pure ashwagandha can cause liver injury in susceptible individuals — but quality control eliminates the additional risk layer of contaminants and adulterants.
What This Means in Practice
| Your Situation | Verdict |
|---|---|
| Healthy adult, stressed, no liver conditions or hepatically-metabolised medications | You can use ashwagandha at standard doses (300–600mg/day) for defined periods. Safety RCTs (PMID: 33338583, n=80) confirm normal liver enzyme profiles at 8 weeks. |
| Pre-existing liver disease (fatty liver, hepatitis, cirrhosis) | Avoid if you have chronic liver disease. Three deaths from acute-on-chronic liver failure were reported in the India case series (PMID: 37756041). This is not appropriate for self-management. Speak with your hepatologist first. |
| On warfarin, cyclosporine, or medications with narrow therapeutic index | Not recommended without explicit clearance from your prescribing doctor. CYP450 interaction risk is real and under-characterised. Consult your healthcare professional. |
| Interested in ashwagandha for NAFLD or liver disease management | Unlikely to help directly. No human trial evidence exists. Preclinical data is interesting but not clinical justification. Consider proven lifestyle interventions (exercise, dietary change, weight management) alongside medical advice instead. |
| Healthy adult wanting stress and cortisol reduction (secondary liver benefit possible) | Evidence-backed. You should start with 300mg twice daily of a root extract. Combine with regular exercise and sleep hygiene for best results. The cortisol-hepatic burden pathway is mechanistically coherent. |
| Pregnant, breastfeeding, or taking immunosuppressants | When not to use: ashwagandha is not effective for these populations as a liver support and may carry additional risks. The 2025 safety review (PMID: 41454545) specifically flags pregnancy and immunosuppression as contraindicated. |
Practical stacking and timing guidance
If you are using ashwagandha for stress reduction with secondary liver benefit in mind, consider combining it with:
- Milk thistle (silymarin): The classic hepatoprotective botanical with human clinical trial support. Pair with ashwagandha for a stress-plus-liver-support stack, though no trial has tested this combination specifically.
- Regular exercise: 150+ minutes per week of moderate activity reduces visceral adiposity and NAFLD risk — alongside ashwagandha’s cortisol effects, this addresses both sides of the Hepatic Burden Equation
- Aim for consistent timing: Take ashwagandha with food to improve absorption and reduce any gastrointestinal discomfort. Morning and evening dosing (300mg each) mirrors the protocol used in the safety RCT (PMID: 33338583).
Monitoring: A Practical Recommendation
For any supplement taken over extended periods, baseline and follow-up blood work is sensible practice. If you are using ashwagandha for more than 12 consecutive weeks, we recommend:
- Baseline liver function panel before starting (AST, ALT, ALP, GGT, bilirubin)
- Follow-up panel at 8–12 weeks
- Discontinue and investigate if ALT rises to more than 3× the upper limit of normal
- Inform your GP you are taking ashwagandha before any blood test interpretation — herb-induced changes can confuse interpretation
- Consider periodic cycling (8–12 weeks on, 2–4 weeks off) as a precautionary measure — this is common practice in traditional Ayurvedic use
This is the same monitoring standard applied in the safety RCT (PMID: 33338583) that confirmed no adverse changes. Replicating that monitoring in your own use is simply sensible medicine.
Frequently Asked Questions
Is ashwagandha good for fatty liver?
There are no human clinical trials testing ashwagandha specifically for fatty liver disease or NAFLD. Animal studies — including rodent models of non-alcoholic steatohepatitis — show that withanolides may reduce hepatic fat accumulation and liver enzyme elevations. These are promising preclinical signals, but preclinical means the evidence exists in animals, not yet in people. If you have diagnosed fatty liver disease, ashwagandha should not replace medical treatment. Speak with your GP before adding it to your routine.
Can ashwagandha cause liver damage?
Yes — in rare cases. Published case reports of drug-induced liver injury (DILI) associated with ashwagandha have been documented across multiple countries. A 2023 Indian case series of 8 patients (PMID: 37756041) confirmed no adulteration — meaning the ashwagandha itself appeared responsible, not a contaminant. Most patients without pre-existing liver disease recovered fully after stopping. Fatalities have been reported in individuals with pre-existing liver conditions. The absolute risk appears low relative to the millions who use it without incident, but it is real. If you have liver disease, avoid ashwagandha without medical supervision.
Does ashwagandha help with NAFLD?
No human trial has directly tested ashwagandha for NAFLD. Rodent studies using high-fat diet models show withanolide-rich extracts may reduce hepatic triglyceride accumulation and oxidative stress — mechanisms relevant to NAFLD. The most plausible indirect benefit in humans is through cortisol reduction: chronically elevated cortisol drives visceral fat accumulation and worsens metabolic liver disease. Ashwagandha has demonstrated cortisol-lowering effects in human RCTs (PMID: 23439798). Whether that translates to measurable liver benefit in NAFLD patients has not been studied.
How does ashwagandha affect the liver?
Ashwagandha interacts with the liver through several pathways. It is metabolised by cytochrome P450 enzymes, meaning it may alter how the liver processes other medications. Withanolides show antioxidant and anti-inflammatory activity in animal liver models. By reducing cortisol, it may indirectly reduce hepatic glucose output and visceral fat accumulation. Critically, rare individuals appear to mount an immune reaction to ashwagandha withanolides, resulting in liver injury. In healthy people at standard doses of 300–600 mg/day root extract, published 8–16 week safety studies show no adverse liver enzyme changes (PMID: 33338583).
How long until ashwagandha helps liver health?
Human evidence for a direct liver benefit does not yet exist — this question cannot be answered with clinical data. What trials do show is that cortisol reduction, a plausible indirect pathway, is measurable within 4–8 weeks at 300–600 mg/day. If you are monitoring liver function, safety studies of 8–16 weeks have not shown adverse changes in healthy adults. If you develop jaundice, dark urine, upper right abdominal discomfort, or unexplained fatigue while taking ashwagandha, stop immediately and see a doctor — these can be early signs of liver stress.
Continue Your Research
- Ashwagandha Benefits: The Complete Evidence-Based Guide
- Ashwagandha Dosage Guide: What Clinical Trials Actually Used
- Ashwagandha Side Effects: The Tolerance Threshold and What 29+ Clinical Trials Reveal
- Ashwagandha for Gut Health: The Stress-Gut Axis Short-Circuit
- Ashwagandha for Heart Health: The Stress-Cardiovascular Relay
- Ashwagandha for Immune Support: The Immunostat Principle
- Ashwagandha and Cancer Research: The Petri Dish Problem
- Ashwagandha for Muscle Strength: The Anabolic Recovery Window Explained